Mabwell's COPD Readout Looks Like a Win. The Field Says It's Too Early to Count It.

At this year's European Respiratory Society meeting, Mabwell — a midsize Chinese biotech — rolled out the headline for 9MW1911, an experimental medicine for the lung disease COPD. At the dose it has picked to carry forward, moderate-to-severe flare-ups were cut by more than 30% versus placebo, severe flare-ups by more than 40%, and the share of patients who suffered a severe flare fell to 13.3% from 35% in the placebo arm. Presented that way, it sounds like a step toward a real drug. It is a step. But this exact corner of drug development has taught investors, expensively, that a good early number here is not the same thing as a drug — and that record is why this readout changes the investment case less than the headline implies.

The mechanism is worth naming. 9MW1911 is an antibody that blocks the ST2 receptor, the doorway for a protein called IL-33 that drives airway inflammation; the goal is to interrupt COPD's cycle of "exacerbations," the flare-ups that send patients to the hospital and inflict permanent lung damage. The addressable market is genuinely large, because most COPD patients are "non-type 2" and fail the blood-eosinophil test required for the already-approved biologic dupilumab. Reaching those patients is real upside, and the pathway is real — which is exactly what makes 9MW1911's position awkward.

Here is the context that matters. The best-in-class version of this idea was already validated this year by a much bigger company: AstraZeneca's tozorakimab, also an IL-33-pathway drug, met its primary endpoint in all three of its pivotal Phase 3 COPD trials, including in the same former-smoker population Mabwell studied. The pathway works; big pharma proved it. The problem is that Mabwell is riding the weaker empirical trail within it. The drug that definitively failed confirmation — Genentech's astegolimab, which like 9MW1911 blocks the ST2 receptor — produced only a 14.5% reduction that missed statistical significance in Phase 3. Its ligand-blocking cousin itepekimab split its two Phase 3 studies: a 27% reduction in one, a near-zero 2% in the other. Only tozorakimab cleared the bar with consistency.

That record is why the specific shape of Mabwell's numbers matters. The treatment cohort at the recommended dose was just 30 patients, and the company disclosed reductions of "more than 30%" and "more than 40%" without stating a p-value. Thirty-patient arms are exactly where this field first looks promising and then fails to survive a larger sample: itepekimab read as a 30–34% reducer at week 24 before its effect faded to 2–12% by week 52 in the replicate trial. A small, unpowered signal in a mechanism that has already produced one Phase 3 failure is a data point for the watch list, not a basis for pricing in a drug.

And there is the question of what 9MW1911 actually is inside Mabwell. The company is a cash-burning, Shanghai-listed small-cap — roughly $1.5 billion in market value, with 2025 revenue up sharply to about ¥625 million but still unprofitable at the operating line — whose strategy is led by a different asset: 9MW2821, a next-generation ADC for solid tumors. 9MW1911 is one intriguing row on an R&D table that has always leaned on its cancer platform. It is also not a stock most US retail investors can own directly: Mabwell trades on China's STAR Market with no US listing or ADR.

The break condition that would actually move this case is still a year or more out. The Phase IIb study is running now; the interim look comes after roughly 120 patients, a real but still modest sample, and Phase III is targeted for the end of 2026. AstraZeneca's three wins raise the bar rather than lower it: the confirmation standard for 9MW1911 has effectively been set by a giant that already de-risked the pathway in the very group Mabwell studied.

The genuinely useful thing the ERS data establishes is that the IL-33/ST2 thesis is real and that Mabwell's antibody is well tolerated and can move the needle in former smokers. The same evidence shows the medicine is still years from a product, in a fight three bigger players have already entered. Against a loss-making operation whose flagship is unconfirmed, that is not yet the divergence the case needs. The evidence says wait for the Phase IIb interim — and watch whether a small developer can be the wave-rider when the giants set the wave.